サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1650976

がん支持療法の世界市場

Cancer Supportive Care

出版日
ページ情報
英文 262 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
がん支持療法の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 262 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん支持療法の世界市場は2030年までに314億米ドルに達する見込み

2024年に276億米ドルと推定されるがん支持療法の世界市場は、2024～2030年の分析期間においてCAGR 2.2%で成長し、2030年には314億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるオピオイドは、CAGR 2.3%を記録し、分析期間終了時には111億米ドルに達すると予想されます。G-CSFsセグメントの成長率は、分析期間中CAGR 1.5%と推定されます。

米国市場は75億米ドルと推定、中国はCAGR 1.9%で成長予測

米国のがん支持療法市場は、2024年には75億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに49億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは1.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.1%と1.5%と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界のがん支持療法市場- 主要動向と促進要因のまとめ

がん支持療法が現代の腫瘍学に不可欠な理由とは？

がん支持療法は、化学療法、放射線療法、外科的介入などの積極的ながん治療を受けている患者の生活の質を高める上で重要な役割を果たし、現代の腫瘍学の基本的な側面となっています。これらの治療は、悪性腫瘍を効果的に標的とする一方で、しばしば疼痛、吐き気、疲労、免疫抑制などの重篤な副作用を伴い、患者の身体的および感情的な幸福に劇的な影響を及ぼすことがあります。支持療法は、幅広い治療法、薬物療法、心理的介入を通じて、これらの副作用を緩和することを目的としています。近年、この分野は大幅に拡大し、従来の疼痛管理や吐き気止め治療だけでなく、貧血、感染症、心理的苦痛に対する介入も含まれるようになった。身体的な症状管理と精神的なサポートを統合するホリスティックなアプローチは、患者が治療計画を遵守するために不可欠であることが証明されています。さらに、がん支持療法は全体的な生活の質を向上させ、患者が尊厳をもって力強く治療に耐えられるようにするものであり、包括的がん治療の重要な要素となっています。

技術革新はがん支持療法をどのように変えていますか？

技術の進歩はがん支持療法に革命をもたらし、がん治療の副作用を管理するためのより正確で効果的、そして患者に優しいソリューションを提供しています。最も注目すべきブレークスルーは、吐き気を長時間緩和する高度制吐剤や、赤血球産生を刺激することで化学療法による貧血に対処する生物学的製剤など、標的を絞った長時間作用型の薬剤の開発です。デジタルヘルス技術が果たす役割はますます大きくなっており、モバイルヘルスアプリケーション、遠隔医療プラットフォーム、ウェアラブルデバイスにより、患者は自宅にいながらリアルタイムのサポートを受け、健康状態をモニターすることができます。これらのツールにより、患者は症状を追跡し、服薬リマインダーを受け取り、ヘルスケアプロバイダーと常に連絡を取り合うことができ、新たな問題に対してタイムリーに介入することができます。さらに、血圧や心拍数などのバイタルサインをモニターするウェアラブル技術は、感染症や脱水などの合併症の兆候を早期に発見し、迅速な治療を可能にし、入院の必要性を減らすことができます。免疫療法や個別化医療における革新もまた、専門的な支持療法の必要性を拡大させています。これらの療法はしばしば、的を絞った管理を必要とする独特の副作用を伴うからです。これらの技術の進歩により、がん支持療法はより正確で利用しやすく、個々の患者のニーズに合ったものとなり、治療アドヒアランスの向上と転帰の改善につながっています。

がん支持療法の主要動向と課題は？

いくつかの重要な動向ががん支持療法市場を再構築しており、より個別化された患者中心の治療へのシフトを反映しています。重要な動向の1つは、患者固有のがん種、治療レジメン、個人の健康特性を考慮した個別化支援ケアプランの利用が拡大していることです。このような個別化されたアプローチは、各患者の固有のニーズに合わせて治療を行う、腫瘍学における精密医療に向けた広範な動きの一部です。もうひとつの重要な動向は、在宅医療への注目が高まっていることです。遠隔医療やデジタルヘルスプラットフォームの出現により、患者は自宅で支持療法を受けられるようになり、頻繁な通院の必要性が減り、全体的な利便性が向上しています。遠隔モニタリングやバーチャルコンサルテーションの台頭により、ヘルスケアプロバイダーは副作用の管理や治療の調整をリアルタイムで行えるようになり、患者の快適性と安全性がさらに向上しています。しかし、この分野は、支持療法、特に新しい生物製剤や特殊な介入にかかる高額な費用など、顕著な課題に直面しています。また、こうしたサービスへのアクセスにも格差があり、特にリソースの少ない環境では、患者があらゆる支持療法を利用できない可能性があります。免疫療法のような最新の治療法は、しばしば予測できない新たな合併症を引き起こすため、複雑な副作用の治療も依然として課題です。このようなハードルにもかかわらず、統合的でホリスティックなケアモデルへのシフトががん支持療法の技術革新を推進し続け、患者により包括的で効果的な症状管理を提供しています。

がん支持療法市場の成長の原動力は？

がん支持療法市場の成長は、世界のがん罹患率の上昇、がん治療の進歩、患者のQOL向上への関心の高まりなど、いくつかの要因によってもたらされます。最も大きな促進要因の1つは、高齢化、ライフスタイルの変化、環境要因に後押しされた世界のがん罹患率の上昇です。化学療法、放射線療法、免疫療法のような積極的な治療を受ける患者が増えるにつれ、それに伴う副作用を管理するための支持療法の必要性が大幅に高まっています。がん治療の革新、特に個別化医療と免疫療法の出現は、これらの治療がしばしば特殊な副作用を伴い、専門的な支持療法を必要とすることから、新たな課題をもたらしています。がん治療における緩和ケアとQOLの重要性が認識されつつあることも、成長を促す大きな要因です。ヘルスケア提供者や政策立案者は、患者ががん治療を生き延びるだけでなく、その過程を通じて幸福を維持できるようにすることをより重視しています。さらに、包括的ながん治療へのアクセスを促進する政府の取り組みや医療政策が、支持療法サービスやインフラへの投資を後押ししています。遠隔医療、遠隔患者モニタリング、在宅ケアオプションなどのデジタル医療技術も、特に農村部や十分なサービスを受けていない地域で支持療法をより利用しやすくし、市場の拡大に寄与しています。これらの要因は、患者中心のケアへの関心の高まりと相まって、がん患者の複雑なニーズを管理するためのより効果的で総合的なソリューションを提供し、がん支持療法市場を前進させ続けています。

セグメント

治療クラス（オピオイド、G-CSFs、NSAIDs、ビスフォスフォネート、ESAs、制吐剤）

調査対象企業の例（注目の16社）

  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10866

Global Cancer Supportive Care Market to Reach US$31.4 Billion by 2030

The global market for Cancer Supportive Care estimated at US$27.6 Billion in the year 2024, is expected to reach US$31.4 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the analysis period. Growth in the G-CSFs segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.5 Billion While China is Forecast to Grow at 1.9% CAGR

The Cancer Supportive Care market in the U.S. is estimated at US$7.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.9 Billion by the year 2030 trailing a CAGR of 1.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Cancer Supportive Care Market - Key Trends and Drivers Summarized

Why Is Cancer Supportive Care Essential in Modern Oncology?

Cancer supportive care has become a fundamental aspect of modern oncology, playing a crucial role in enhancing the quality of life for patients undergoing aggressive cancer treatments such as chemotherapy, radiation therapy, and surgical interventions. These treatments, while targeting the malignancy effectively, often come with severe side effects, including pain, nausea, fatigue, and immune suppression, which can drastically affect a patient’s physical and emotional well-being. Supportive care aims to alleviate these adverse effects through a wide range of therapies, medications, and psychological interventions. In recent years, this field has expanded significantly, encompassing not just traditional pain management and anti-nausea treatments but also interventions for anemia, infections, and psychological distress. Holistic approaches that integrate physical symptom management with emotional support have proven to be essential in helping patients adhere to their treatment plans. Moreover, cancer supportive care helps improve the overall quality of life, ensuring that patients can endure their treatment with dignity and strength, making it a critical component of comprehensive cancer care.

How Are Technological Innovations Transforming Cancer Supportive Care?

Technological advancements have revolutionized cancer supportive care, offering more precise, effective, and patient-friendly solutions to manage the side effects of cancer treatments. One of the most notable breakthroughs is the development of targeted and long-acting medications, such as advanced antiemetic drugs that provide prolonged relief from nausea or biologics that address chemotherapy-induced anemia by stimulating red blood cell production. Digital health technologies are playing an increasingly significant role, with mobile health applications, telemedicine platforms, and wearable devices enabling patients to receive real-time support and monitor their health status from the comfort of their homes. These tools allow patients to track symptoms, receive medication reminders, and stay in constant communication with their healthcare providers, ensuring timely interventions for any emerging issues. In addition, wearable technology, which monitors vital signs like blood pressure and heart rate, can detect early signs of complications such as infection or dehydration, allowing for prompt treatment and reducing the need for hospitalization. Innovations in immunotherapies and personalized medicine have also expanded the need for specialized supportive care, as these therapies often come with unique side effects that require targeted management. Collectively, these technological advances are making cancer supportive care more precise, accessible, and tailored to individual patient needs, leading to better treatment adherence and improved outcomes.

What Are the Key Trends and Challenges in Cancer Supportive Care?

Several significant trends are reshaping the cancer supportive care market, reflecting a shift toward more personalized, patient-centered care. One of the key trends is the growing use of individualized supportive care plans, which take into account a patient’s specific cancer type, treatment regimen, and personal health characteristics. This personalized approach is part of the broader movement toward precision medicine in oncology, where treatments are tailored to the unique needs of each patient. Another important trend is the increasing focus on home-based care. With the advent of telemedicine and digital health platforms, patients can now receive supportive care from their homes, reducing the need for frequent hospital visits and improving overall convenience. The rise of remote monitoring and virtual consultations has made it possible for healthcare providers to manage side effects and adjust treatments in real-time, further enhancing patient comfort and safety. However, the field faces notable challenges, including the high cost of supportive care treatments, particularly for newer biologics and specialized interventions. There are also disparities in access to these services, especially in low-resource settings, where patients may not have access to the full range of supportive care options. Managing the complex side effects of modern treatments like immunotherapy also remains a challenge, as these therapies often introduce new and unpredictable complications. Despite these hurdles, the shift toward integrated, holistic care models continues to drive innovation in cancer supportive care, offering patients more comprehensive and effective management of their symptoms.

What’s Driving the Growth in the Cancer Supportive Care Market?

The growth in the cancer supportive care market is driven by several factors, including the rising global incidence of cancer, advancements in cancer treatments, and the increasing focus on improving patient quality of life. One of the most significant drivers is the global rise in cancer cases, fueled by aging populations, lifestyle changes, and environmental factors. As more patients undergo aggressive treatments like chemotherapy, radiation, and immunotherapy, the need for supportive care to manage the associated side effects has grown substantially. Innovations in cancer treatments, particularly the advent of personalized medicine and immunotherapies, have introduced new challenges, as these therapies often come with unique side effects that require specialized supportive care interventions. Another major factor driving growth is the increasing recognition of the importance of palliative care and quality of life in cancer treatment. Healthcare providers and policymakers are placing a greater emphasis on ensuring that patients not only survive their cancer treatment but also maintain their well-being throughout the process. In addition, government initiatives and healthcare policies that promote access to comprehensive cancer care have boosted investments in supportive care services and infrastructure. Digital health technologies, including telemedicine, remote patient monitoring, and home-based care options, are also contributing to the expansion of the market by making supportive care more accessible, particularly in rural and underserved areas. These factors, combined with the growing focus on patient-centered care, continue to propel the cancer supportive care market forward, offering more effective and holistic solutions to manage the complex needs of cancer patients.

SCOPE OF STUDY:

The report analyzes the Cancer Supportive Care market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Class (Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs, Antiemetics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 16 Featured) -

  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Cancer Supportive Care - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Cancer Incidence Globally Spurs Growth in Demand for Cancer Supportive Care Solutions
    • Advances in Chemotherapy and Radiation Treatments Throw the Spotlight on Supportive Care Needs
    • Focus on Patient-Centered Care Expands Addressable Market Opportunity for Supportive Therapies
    • Growth in Palliative Care Programs Propels Demand for Cancer Supportive Care Medications
    • Increasing Focus on Nutritional Support and Supplements Sustains Growth in Cancer Supportive Care Market
    • Technological Innovations in Digital Health Generate New Opportunities for Cancer Supportive Care Monitoring
    • Growing Awareness About Managing Treatment-Related Side Effects Propels Market Expansion
    • Rising Adoption of Home Healthcare Expands Market Potential for Cancer Supportive Care Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Supportive Care Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for G-CSFs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for ESAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • JAPAN
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • CHINA
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: China 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • EUROPE
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • FRANCE
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: France 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • GERMANY
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Germany 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Italy 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: UK 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Rest of World 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2015, 2025 & 2030

IV. COMPETITION